Sarepta Therapeutics, Inc.
$13.33-$0.84 (-5.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.8B
- P/E
- -2.5x
- EV / EBITDA
- -3.2x
- Revenue
- $2.2B
- Net margin
- -32.5%
- ROCE
- -29.2%
Price chart
Technical chartScreen technicals →-19.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -30.5%
- 3M
- -30.6%
- 6M
- -22.1%
- 1Y
- -19.1%
- 5Y
- -83.3%
52-week range
Day change -$0.84 (-5.9%) from $14 to $13 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in SRPT, bought on each weekday since 2021.
News & filings
What Sarepta Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 713 million US dollars in fiscal 2025.
Strengths (1)
- Cash on the balance sheet equals 46% of the company's market value.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Read moreShow less
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 105.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.8B
- P/E
- -2.5x
- P/B
- 1.5x
- EV / EBITDA
- -3.2x
- EV / Sales
- 0.9x
- P/S
- 0.8x
- 52-week high
- $23.83
- 52-week low
- $13.33
Profitability
- Operating margin
- -29.9%
- Net margin
- -32.5%
- EBITDA margin
- -28.2%
- ROE
- -62.5%
- ROCE
- -29.2%
- ROA
- -21.3%
- Asset turnover
- 0.66
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $2.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 15.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 33.1%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -403.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$315.3M
Solvency
- Current ratio
- 2.32
- Debt / Equity
- 0.91
- Debt / Assets
- 0.31
- CFO / Net profit
- 0.29
- Cash / Market cap
- 45.6%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $2.2B |
| Cost of revenue | $839.6M |
| Gross profit | $1.4B |
| Operating expenses | $2.0B |
| Research and development | $1.5B |
| Selling, general and administrative | $491.7M |
| Operating income | -$657.8M |
| Interest and other | -$44.5M |
| Pretax income | -$702.2M |
| Tax and other | $11.2M |
| Net income | -$713.4M |
Revenue and net profit
Revenue grew 15.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $933.0M | -$703.5M |
| FY2023 | $1.2B | -$536.0M |
| FY2024 | $1.9B | $235.2M |
| FY2025 | $2.2B | -$713.4M |
Cash flows
FY2025: -$205.5M from operations, -$315.3M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$325.3M | -$357.6M |
| FY2023 | -$501.0M | -$588.3M |
| FY2024 | -$205.8M | -$352.7M |
| FY2025 | -$205.5M | -$315.3M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $2.2B+15.6%1Y
- EBITDA
- -$619.6M-295.5%1Y
- Net profit
- -$713.4M-403.3%1Y
- Cash from operations
- -$205.5M
- Free cash flow
- -$315.3M
- Revenue CAGR, 3Y
- 33.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.2B | -$619.6M | -$713.4M | -$315.3M | -62.5% | +15.6% | -403.3% |
Monthly returns
Month-by-month returns of SRPT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $3.3B |
| Current assets | $2.5B |
| Non-current assets | $811.8M |
| Liabilities | $2.2B |
| Current liabilities | $1.1B |
| Non-current liabilities | $1.1B |
| Equity | $1.1B |
| Paid-in capital | $6.0B |
| Retained earnings | -$4.9B |
| Treasury stock | $25.3M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; SRPT highlighted.
P/E against peers
SRPT has no positive P/E; the peer median is 12.8x.
Not shown (no positive earnings and no EV / Sales): Sarepta Therapeutics, Inc., Acadia Healthcare Company, Inc., Neogen Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPTthis company | $1.8B | -2.5x | 1.5x | -62.5% | -3.2x |
| TransMedics Group, Inc.TMDX | $2.5B | 13.0x | 5.2x | 40.2% | 16.8x |
| Acadia Healthcare Company, Inc.ACHC | $2.3B | -2.1x | 1.2x | -56.6% | -6.5x |
| Prestige Consumer Healthcare Inc.PBH | $2.2B | 11.3x | 1.1x | 10.1% | 9.5x |
| LeMaitre Vascular, Inc.LMAT | $2.1B | 37.0x | 5.4x | 14.7% | 25.3x |
| Select Medical Holdings CorporationSEM | $2.0B | 14.0x | 1.2x | 8.6% | 9.2x |
| Neogen CorporationNEOG | $2.0B | -1.8x | 1.0x | -52.7% | -2.9x |
| ADMA Biologics, Inc.ADMA | $1.8B | 12.6x | 3.9x | 30.8% | 9.3x |
| Phibro Animal Health CorporationPAHC | $1.3B | 27.8x | 4.7x | 16.9% | 13.8x |
| Peer median | — | 12.8x | 2.5x | 12.4% | 9.4x |
Year-to-date ROI
SRPT since 1 January, against earlier years.
Historical volatility
SRPT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -57.5% |
| FY2023 | -21.5% |
| FY2024 | 11.5% |
| FY2025 | -29.9% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $2.2B |
| Cost of revenueCost Of Revenue | $839.6M |
| Gross profitGross Profit | $1.4B |
| Operating expensesOperating Expense | $2.0B |
| Research and developmentResearch And Development | $1.5B |
| Selling, general and administrativeSelling General And Administration | $491.7M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $2.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $2.6M |
| Amortization | $2.6M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $2.6M |
| Total expensesTotal Expenses | $2.9B |
| Operating incomeOperating Income | -$657.8M |
| Interest and other | |
| Pretax incomePretax Income | -$702.2M |
| TaxTax Provision | $11.2M |
| Net incomeNet Income | -$713.4M |
| Per share | |
| Supplementary | |
| Other lines |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $3.3B |
| Current assetsCurrent Assets | $2.5B |
| Non-current assetsTotal Non Current Assets | $811.8M |
| LiabilitiesTotal Liabilities Net Minority Interest | $2.2B |
| Current liabilitiesCurrent Liabilities | $1.1B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.1B |
| EquityTotal Equity Gross Minority Interest | $1.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$205.5M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$205.5M |
| Net income, continuing operationsNet Income From Continuing Operations | -$713.4M |
| Depreciation and amortisationDepreciation And Amortization | $44.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $44.5M |
| Amortization of securitiesAmortization Of Securities | -$5.3M |
| Stock-based compensationStock Based Compensation | $123.4M |
| Operating gains and lossesOperating Gains Losses | $14.4M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $13.9M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $17.3M |
| Asset impairmentAsset Impairment Charge | $182.3M |
| Change in working capitalChange In Working Capital | $78.0M |
| Other non-cash itemsOther Non Cash Items | $70.6M |
| Investing cash flowInvesting Cash Flow | $69.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $69.6M |
| Capital expenditureCapital Expenditure | -$109.8M |
| Purchase of PP&EPurchase Of PPE | -$102.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$102.0M |
| AcquisitionsPurchase Of Business | — |
| DisposalsSale Of Business | $174.1M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $174.1M |
| Purchase of investmentsPurchase Of Investment | -$290.5M |
| Sale of investmentsSale Of Investment | $295.9M |
| Net investment purchases and salesNet Investment Purchase And Sale | $5.4M |
| Purchase of intangiblesPurchase Of Intangibles | -$7.9M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$7.9M |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | -$168.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$168.3M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$162.6M |
| Net debt issuedNet Issuance Payments Of Debt | -$162.6M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$162.6M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$162.6M |
| Shares issuedIssuance Of Capital Stock | $20.0M |
| Common stock issuedCommon Stock Issuance | $20.0M |
| Net common stock issuedNet Common Stock Issuance | -$5.0M |
| Common stock repurchasedCommon Stock Payments | -$25.0M |
| Share buybacksRepurchase Of Capital Stock | -$25.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $18.7M |
| Other financing chargesNet Other Financing Charges | -$19.4M |
| Change in cashChanges In Cash | -$304.2M |
| Cash at the start of the yearBeginning Cash Position | $1.1B |
| Cash at the end of the yearEnd Cash Position | $814.4M |
| Free cash flowFree Cash Flow | -$315.3M |
| Supplemental |
Learn while you research
Academy chapters picked for Sarepta Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read